Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
c-ATT regimen (Sun Yat-sen University)
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
c-ATT is an intensive sequential chemotherapy regimen developed by Sun Yat-sen University for the treatment of untreated high-risk T-cell lymphoma. The regimen consists of three alternating protocols administered sequentially: CHOP-B (cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin), IMVP-16 (ifosfamide, methotrexate, and etoposide), and DHAP (dexamethasone, cytarabine, and cisplatin). This approach is designed to improve therapeutic efficacy over standard CHOP therapy by utilizing a broad range of non-cross-resistant cytotoxic agents to overcome drug resistance in aggressive T-cell lymphomas.
- Other names
- CHOP-B/IMVP-16/DHAP regimen
02
Targets
TOP2A (DNA topoisomerase II)CRBN (Cereblon)DHFR (Dihydrofolate reductase)DNA polymerase familyGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on c-ATT regimen (Sun Yat-sen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on c-ATT regimen (Sun Yat-sen University).